279215-39-3

Upstream product

• 1576-35-8 toluene-4-sulfonic acid hydrazide 
• 180740-63-0 (2E,4E,6E)-7-[3-tert-Butyl-5-(1,1-dimethyl-2-oxo-ethyl)-phenyl]-3-methyl-octa-2,4,6-trienoic acid ethyl ester 
• 41891-54-7 diethyl 3-(ethoxycarbonyl)-3-methylprop-2-en-yl phosphate 
• 180740-53-8 1-[3-tert-butyl-5-(1-hydroxyethyl)phenyl]ethanol 
• 180740-56-1 1-[3-tert-butyl-5-(1-hydroxyethyl)phenyl]-2-methylpropionaldehyde 
• 203584-37-6 2-[3-tert-Butyl-5-(1-hydroxy-ethyl)-phenyl]-2-methyl-propan-1-ol 
• 180740-57-2 1-[3-tert-butyl-5-(2-hydroxy-1,1-dimethylethyl)phenyl]ethanone 
• 180740-54-9 1-{3-tert-Butyl-5-[1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-phenyl}-ethanol 
• 180740-55-0 1-{3-tert-Butyl-5-[1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-phenyl}-ethanone 
• 180740-62-9 (2E,4E,6E)-7-[3-tert-Butyl-5-(2-hydroxy-1,1-dimethyl-ethyl)-phenyl]-3-methyl-octa-2,4,6-trienoic acid ethyl ester 
• 180740-58-3 1-{3-tert-Butyl-5-[2-(tert-butyl-diphenyl-silanyloxy)-1,1-dimethyl-ethyl]-phenyl}-ethanone 
• 180740-60-7 (E)-3-{3-tert-Butyl-5-[2-(tert-butyl-diphenyl-silanyloxy)-1,1-dimethyl-ethyl]-phenyl}-but-2-enal 
• 180740-61-8 (2E,4E,6E)-7-{3-tert-Butyl-5-[2-(tert-butyl-diphenyl-silanyloxy)-1,1-dimethyl-ethyl]-phenyl}-3-methyl-octa-2,4,6-trienoic acid ethyl ester 
• 180740-59-4 (E)-3-{3-tert-Butyl-5-[2-(tert-butyl-diphenyl-silanyloxy)-1,1-dimethyl-ethyl]-phenyl}-but-2-enenitrile 

Downstream Products

• 178600-20-9 LGD₁₅₅₀ 
• 1026330-60-8 C₂₅H₃₅⁽²⁾HO₂ 
• 178688-27-2 ethyl (2E, 4E, 6E)-7-(3,5-di-t-butylphenyl)-3-methylocta-2,4,6-trienoate 

Relevant academic research and scientific papers

Synthesis and characterization of a highly potent and selective isotopically labeled retinoic acid receptor ligand, ALRT1550

The syntheses of two labeled homologues of (2E,4E,6E)-7-(3,5-di-tert- butylphenyl)-3-methylocta-2,4,6-trienoic acid (ALRT1550, 2), [13CD3]ALRT1550 (3) and [3H]ALRT1550 (4), are described in this report. ALRT1550 is an exceptionally potent antiproliferative agent which is currently in phase I/II clinical trials for acute chemotherapy. Both homologues were prepared from commercially available 3,5-di-tert-butylbenzoic acid. Homologue [13CD3]ALRT1550 was labeled at the 7-position of the trienoic acid chain via addition of [13CD3]MgI to a Weinreb amide precursor. The preparation of [3H]ALRT1550 utilized novel methodology to synthesize a sterically hindered and site-specific tritium-labeled tert- butyl group. Saturation binding and Scatchard analysis of this ligand at the retinoic acid receptors are also described, along with competition binding (K(i)) values for a series of known retinoids using [3H]ALRT1550 or [3H]ATRA as the labeled probes.